Effect of low-dose esketamine on quality of recovery after gynecologic laparoscopic surgery: a randomized controlled trial
In brief
Esketamine raises recovery scores 2.3 points after gynecologic laparoscopy, below meaningful threshold
In a randomized trial of 140 adults, low-dose esketamine modestly increased 24-hour recovery scores after gynecologic laparoscopy, but the difference fell below the threshold for a clinically meaningful improvement. Pain scores were also lower at some time points, while dizziness was more common shortly after surgery; whether these small benefits matter in practice remains unclear.
- Journal
- BMC anesthesiology (Q1)
- Published
- 11 September 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Wenli He, Chen Chen, Xinhai Wu, Ying Shan, Yanling Wei, Hongqin Li, et al.
- PMID
- 43052744
- DOI
- 10.1186/s12871-026-04239-3
Why clinicians should know about it
- Picked for Anesthesiology and Pain Medicine (paper of the day, 21 November 2026): Randomized trial tests esketamine analgesia and postoperative recovery
Abstract
BACKGROUND: Although low-dose esketamine has shown analgesic benefits, its effect on the quality of recovery after gynecologic laparoscopy remains unclear. METHODS: In this double-blind randomized controlled trial, 140 adults with ASA I-II and a BMI of 18.5-30 kg/m² undergoing elective gynecologic laparoscopy (hysterectomy, myomectomy, or ovarian cystectomy) were randomly assigned to Group E (esketamine group) or Group C (control group). Patients in Group E received 0.25 mg/kg esketamine bolus after anesthesia induction followed by a continuous infusion of 0.1 mg/kg/h until 15 min before the end of surgery, whereas those in Group C received an equal volume of normal saline. The primary outcome was the total score on the Quality of Recovery-40 questionnaire (QoR-40) at 24 h postoperatively. Secondary outcomes included Numeric Rating Scale (NRS) scores at rest and during activity at 0, 6, 12, and 24 h postoperatively, tracheal extubation time, rescue analgesic consumption, and the incidences of nausea, vomiting, dizziness, and nightmares. RESULTS: Group E had significantly higher global QoR-40 scores than Group C at 24 h postoperatively (adjusted mean difference 2.30, 95% CI 0.21 to 4.39; P = 0.034). Pain scores at rest and during activity were lower in Group E at 6 h (rest: mean (SD), 2.28 (1.69) vs. 3.01 (2.09), P = 0.025; activity: 3.03 (1.80) vs. 3.81 (2.08), P = 0.020) and 24 h (rest: 1.88 (1.30) vs. 2.29 (1.32), P = 0.045; activity: 2.56 (1.43) vs. 3.16 (1.60), P = 0.022), but were comparable between groups at 0 h and 12 h. The incidence of dizziness was significantly higher in Group E than in Group C during the PACU period (23.5% vs. 8.7%; risk difference (RD) 14.8%, 95% CI 2.8% to 26.9%; P = 0.033). However, this difference resolved by 24 h postoperatively (25.0% vs. 23.2%; P = 0.962), and no significant differences were observed in other secondary outcomes. CONCLUSIONS: Low-dose esketamine was associated with a statistically higher QoR-40 score, but the magnitude was below the Minimum Clinically Important Difference (MCID) and therefore may not represent a clinically meaningful improvement in gynecologic laparoscopy. TRIAL REGISTRATION: The trial was registered at the Chinese Clinical Trials Registry ( www.chictr.org.cn , registration number: ChiCTR2300072538, date of registration: 16/06/2023).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.